Clinical trials: Gastroparesis
Gastroparesis, Slow Transit Constipation
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
The study objective is to demonstrate the equivalence of the Atmo Motility Gas Capsule System with the predicate SmartPill in measuring gastric emptying time and colonic transit time through examination of device agreement.
- Conditions
- Gastroparesis, Slow Transit Constipation, IBS
- Trial name
- NCT05718505
- Testing
- Atmo Motility Gas Capsule System, SmartPill Monitoring System
- Where
- 2 sites in United States
- Volunteers
- 209 people
- Sponsor
- Atmo Biosciences Pty Ltd
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Idiopathic Gastroparesis, Diabetic Gastroparesis
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT06836557
- Testing
- Tradipitant
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 17 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Diabetic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
- Trial name
- NCT05832151
- Testing
- CIN-102 Dose 15mg or 10mg
- Where
- 100 sites in United States
- Volunteers
- 382 people
- Sponsor
- CinDome Pharma, Inc.
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.
- Trial name
- NCT04303195
- Testing
- NG101
- Where
- 83 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurogastrx, Inc.
Gastroparesis, Diabetic Gastroparesis
Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant
- Trial name
- NCT04474990
- Testing
- Tradipitant
- Where
- 15 sites in United States
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Gastroparesis, Gastroparesis Nondiabetic
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- RESTING (NCT05980455)
- Testing
- Enterra® Therapy System
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Gastroparesis, Gastroparesis Nondiabetic
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life…
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- EXPEDITE (NCT06560307)
- Testing
- Enterra Therapy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Gastroparesis
Establishing a Pediatric Reference Range for the 13C-Spirulina Gastric Emptying Breath Test (GEBT)
The goal of this clinical trial is to define the normal response to the 13C-Spirulina Gastric Emptying Breath Test (GEBT) in children, so that we can use this test to help diagnose children that are suspected of having a…
- Trial name
- NCT06004596
- Testing
- 13C-Spirulina Gastric Emptying Breath Test (GEBT), 13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat
- Where
- 3 sites in United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Gastroparesis
Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
The Vibrant capsule is a novel vibrating device for the treatment of gastrointestinal disorders. The effect of different vibrations on the motor functions of the gastrointestinal tract are unclear.
- Trial name
- NCT02736799
- Testing
- Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vibrant Ltd.
Gastroparesis
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will…
- Trial name
- NCT02970968
- Testing
- VLY-686 (Tradipitant)
- Where
- 38 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis, Slow Transit
Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients
This study will compare gastrointestinal transit time measured by the SmartPill and the Atmo gas capsule in patients with gastrointestinal motility disorders.
- Trial name
- NCT04977063
- Testing
- Atmo gas capsule, SmartPill
- Where
- 3 sites in Australia
- Volunteers
- 53 people
- Sponsor
- Atmo Biosciences Pty Ltd
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
- Trial name
- NCT03544229
- Testing
- TAK-906 Maleate
- Where
- 109 sites in United States, Belgium and 2 more
- Volunteers
- 242 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastroparesis
GEBT Lot-to-Lot and Biological Variability
The purpose of this study is to collect information regarding lot-to-lot variability in 13C-Spirulina test meal lets and within-subject biological variability.
- Trial name
- NCT04772261
- Testing
- 13C-Spirulina GEBT
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Gastroparesis
A Study of CNSA-001 in Women With Diabetic Gastroparesis
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or…
- Trial name
- NCT03712124
- Testing
- CNSA-001
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- PTC Therapeutics